<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852406</url>
  </required_header>
  <id_info>
    <org_study_id>2020-432</org_study_id>
    <nct_id>NCT04852406</nct_id>
  </id_info>
  <brief_title>Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy</brief_title>
  <official_title>Effect of Protocol-based Management on Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy: a Pragmatic Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pragmatic interventional study is to evaluate whether a protocol-based&#xD;
      management of antithrombotic drugs can reduce a composite of perioperative outcomes in&#xD;
      patients with chronic antithrombotic therapy before surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aging population and chronic medical disease make the management of surgical patients more&#xD;
      complex. About one tenth of patients scheduled for surgery are taking antithrombotic&#xD;
      medications. Coagulation disturbance induced by these medications may increase the risk of&#xD;
      bleeding, whereas withholding these medications may increase the risk of thrombotic events.&#xD;
      It is a dilemma when managing these patients.&#xD;
&#xD;
      The guidelines and expert consensus published by multiple disciplinary teams constitute the&#xD;
      perioperative antithrombotic management protocols. However, the effects of perioperative&#xD;
      antithrombotic management guided by these guidelines or expert consensus are seldom reported.&#xD;
      The investigators hypothesize that a protocol-based perioperative antithrombotic management&#xD;
      can benefit patients with chronic antithrombotic therapy before surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of a composite outcome including major bleeding and major adverse cardiovascular or cerebrovascular events</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Major bleeding indicates bleeding of type 2 or higher on the BARC (Bleeding Academic Research Consortium) criteria. Major adverse cardiovascular or cerebrovascular events indicate acute coronary syndrome, acute myocardium infarction, ischemic stroke/transient ischemic attack, systemic arterial embolism, pulmonary embolism, or all-cause death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of other postoperative complications</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Other postoperative complications indicate any newly occurred medical events that are harmful to patients' recovery and required therapeutic intervention, except major bleeding and major adverse cardiovascular or cerebrovascular events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of hospital stay</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>The length of hospital stay from admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total expenses during hospitalization</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Total expenses during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate within 30 days after surgery</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>All-cause mortality rate within 30 days after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">526</enrollment>
  <condition>Antithrombotic Therapy</condition>
  <condition>Perioperative Care</condition>
  <condition>Perioperative Outcomes</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group receive protocol-based management of perioperative antithrombotic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants in this group receive routine management of perioperative antithrombotic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Protocol-based management of perioperative antithrombotic therapy</intervention_name>
    <description>Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Protocol-based management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Routine management of perioperative antithrombotic therapy</intervention_name>
    <description>Perioperative antithrombotic therapy is managed according to current routine practice.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Routine management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients with continuing antithrombotic therapy (including antiplatelet and/or&#xD;
             anticoagulant therapies) for cardiovascular and cerebrovascular diseases for more than&#xD;
             2 weeks.&#xD;
&#xD;
          -  2. Patients who have one or more of the following situations: (1) non-valvular atrial&#xD;
             fibrillation with a CHA2DS2-VASc score &gt;4; (2) post-artificial valve replacement&#xD;
             (including mitral valve, ball-cage valve or tilting disc aortic valve); (3) venous&#xD;
             thromboembolism occurred within 1 year, or venous thromboembolism with other high-risk&#xD;
             factors which require long-term anticoagulation treatment; (4) coronary heart disease&#xD;
             with coronary stent implantation, thrombolytic therapy or other coronary procedures&#xD;
             within 2 years, or who had undergone coronary artery bypass grafting within 1 year, or&#xD;
             who experienced myocardial infarction or acute coronary syndrome within 1 year; (5) a&#xD;
             history of stroke/transient ischemic accident within 1 year, or a history of cervical&#xD;
             or intracranial revascularization treatment within 1 year; (6) peripheral arterial&#xD;
             disease.&#xD;
&#xD;
          -  3. Patients who are scheduled to undergo intra-abdominal surgery (including general&#xD;
             and urologic surgery).&#xD;
&#xD;
          -  4. Patients who sign written informed consents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Refuse to participate.&#xD;
&#xD;
          -  2. Emergency surgery.&#xD;
&#xD;
          -  3. Unable to complete the preoperative assessment and follow-up plan.&#xD;
&#xD;
          -  4. Other reasons that are considered unsuitable for study participation by the&#xD;
             investigators or the attending doctors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Zhang, MD</last_name>
    <phone>86 10 83572784</phone>
    <email>zhanghong40@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huai-Jin Li, MD</last_name>
    <email>crystal_35@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Zhang, MD</last_name>
      <phone>86 10 83572784</phone>
      <email>zhanghong40@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hornor MA, Duane TM, Ehlers AP, Jensen EH, Brown PS Jr, Pohl D, da Costa PM, Ko CY, Laronga C. American College of Surgeons' Guidelines for the Perioperative Management of Antithrombotic Medication. J Am Coll Surg. 2018 Nov;227(5):521-536.e1. doi: 10.1016/j.jamcollsurg.2018.08.183. Epub 2018 Aug 24. Review.</citation>
    <PMID>30145286</PMID>
  </reference>
  <reference>
    <citation>Dubois V, Dincq AS, Douxfils J, Ickx B, Samama CM, Dogné JM, Gourdin M, Chatelain B, Mullier F, Lessire S. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017 May 15;15:14. doi: 10.1186/s12959-017-0137-1. eCollection 2017. Review.</citation>
    <PMID>28515674</PMID>
  </reference>
  <reference>
    <citation>Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol. 2003 Nov;123(4):676-82.</citation>
    <PMID>14616972</PMID>
  </reference>
  <reference>
    <citation>Oltmann SC, Alhefdhi AY, Rajaei MH, Schneider DF, Sippel RS, Chen H. Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures. Ann Surg Oncol. 2016 Sep;23(9):2874-82. doi: 10.1245/s10434-016-5241-0. Epub 2016 May 2.</citation>
    <PMID>27138383</PMID>
  </reference>
  <reference>
    <citation>Yurttas T, Wanner PM, Filipovic M. Perioperative management of antithrombotic therapies. Curr Opin Anaesthesiol. 2017 Aug;30(4):466-473. doi: 10.1097/ACO.0000000000000481. Review.</citation>
    <PMID>28509773</PMID>
  </reference>
  <reference>
    <citation>Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017 Dec 13;17(1):295. doi: 10.1186/s12872-017-0719-7. Review.</citation>
    <PMID>29237411</PMID>
  </reference>
  <reference>
    <citation>Childers CP, Maggard-Gibbons M, Ulloa JG, MacQueen IT, Miake-Lye IM, Shanman R, Mak S, Beroes JM, Shekelle PG. Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review. Syst Rev. 2018 Jan 10;7(1):4. doi: 10.1186/s13643-017-0635-z.</citation>
    <PMID>29321066</PMID>
  </reference>
  <reference>
    <citation>Howell SJ, Hoeks SE, West RM, Wheatcroft SB, Hoeft A; OBTAIN Investigators of European Society of Anaesthesiology (ESA) Clinical Trial Network. Prospective observational cohort study of the association between antiplatelet therapy, bleeding and thrombosis in patients with coronary stents undergoing noncardiac surgery. Br J Anaesth. 2019 Feb;122(2):170-179. doi: 10.1016/j.bja.2018.09.029. Epub 2018 Dec 15.</citation>
    <PMID>30686302</PMID>
  </reference>
  <reference>
    <citation>Widimský P, Moťovská Z, Havlůj L, Ondráková M, Bartoška R, Bittner L, Dušek L, Džupa V, Knot J, Krbec M, Mencl L, Pachl J, Grill R, Haninec P, Waldauf P, Gürlich R. Perioperative cardiovascular complications versus perioperative bleeding in consecutive patients with known cardiac disease undergoing non-cardiac surgery. Focus on antithrombotic medication. The PRAGUE-14 registry. Neth Heart J. 2014 Sep;22(9):372-9. doi: 10.1007/s12471-014-0575-3.</citation>
    <PMID>25120211</PMID>
  </reference>
  <reference>
    <citation>Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, Stefanini GG, Angiolillo DJ, Capodanno D, Urban P, Morice MC, Krucoff M, Goel R, Roumeliotis A, Sweeny J, Sharma SK, Kini A. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol. 2020 Jun 2;75(21):2711-2722. doi: 10.1016/j.jacc.2020.03.070.</citation>
    <PMID>32466887</PMID>
  </reference>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>July 10, 2021</last_update_submitted>
  <last_update_submitted_qc>July 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>perioperative care</keyword>
  <keyword>antithrombotic therapy</keyword>
  <keyword>perioperative outcomes</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>on demands.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

